![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: POMGNT2 |
Gene summary for POMGNT2 |
![]() |
Gene information | Species | Human | Gene symbol | POMGNT2 | Gene ID | 84892 |
Gene name | protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-) | |
Gene Alias | AGO61 | |
Cytomap | 3p22.1 | |
Gene Type | protein-coding | GO ID | GO:0001764 | UniProtAcc | A0A024R2P4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84892 | POMGNT2 | LZE24T | Human | Esophagus | ESCC | 2.29e-04 | 7.32e-02 | 0.0596 |
84892 | POMGNT2 | P2T-E | Human | Esophagus | ESCC | 4.32e-08 | 1.54e-01 | 0.1177 |
84892 | POMGNT2 | P4T-E | Human | Esophagus | ESCC | 2.41e-12 | 1.95e-01 | 0.1323 |
84892 | POMGNT2 | P8T-E | Human | Esophagus | ESCC | 6.06e-17 | 1.24e-01 | 0.0889 |
84892 | POMGNT2 | P9T-E | Human | Esophagus | ESCC | 2.07e-02 | 4.66e-02 | 0.1131 |
84892 | POMGNT2 | P10T-E | Human | Esophagus | ESCC | 5.45e-15 | 1.13e-01 | 0.116 |
84892 | POMGNT2 | P11T-E | Human | Esophagus | ESCC | 1.14e-07 | 2.54e-01 | 0.1426 |
84892 | POMGNT2 | P12T-E | Human | Esophagus | ESCC | 2.60e-14 | 3.08e-01 | 0.1122 |
84892 | POMGNT2 | P15T-E | Human | Esophagus | ESCC | 3.23e-03 | 6.47e-02 | 0.1149 |
84892 | POMGNT2 | P16T-E | Human | Esophagus | ESCC | 2.84e-20 | 2.16e-01 | 0.1153 |
84892 | POMGNT2 | P17T-E | Human | Esophagus | ESCC | 1.70e-02 | 1.17e-01 | 0.1278 |
84892 | POMGNT2 | P20T-E | Human | Esophagus | ESCC | 1.62e-06 | 1.25e-01 | 0.1124 |
84892 | POMGNT2 | P22T-E | Human | Esophagus | ESCC | 4.53e-18 | 2.05e-01 | 0.1236 |
84892 | POMGNT2 | P23T-E | Human | Esophagus | ESCC | 9.68e-12 | 2.43e-01 | 0.108 |
84892 | POMGNT2 | P24T-E | Human | Esophagus | ESCC | 2.93e-06 | 1.02e-01 | 0.1287 |
84892 | POMGNT2 | P26T-E | Human | Esophagus | ESCC | 1.06e-19 | 3.13e-01 | 0.1276 |
84892 | POMGNT2 | P27T-E | Human | Esophagus | ESCC | 1.68e-12 | 1.45e-01 | 0.1055 |
84892 | POMGNT2 | P28T-E | Human | Esophagus | ESCC | 1.20e-10 | 1.23e-01 | 0.1149 |
84892 | POMGNT2 | P31T-E | Human | Esophagus | ESCC | 4.70e-02 | 4.44e-03 | 0.1251 |
84892 | POMGNT2 | P32T-E | Human | Esophagus | ESCC | 2.32e-06 | 6.28e-02 | 0.1666 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Breast | Precancer | ![]() |
Breast | IDC | ![]() |
Breast | DCIS | ![]() |
Cervix | CC | ![]() |
Cervix | HSIL_HPV | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
GO:00064931 | Esophagus | ESCC | protein O-linked glycosylation | 51/8552 | 86/18723 | 7.54e-03 | 2.70e-02 | 51 |
GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
POMGNT2 | SNV | Missense_Mutation | c.1390N>C | p.Val464Leu | p.V464L | Q8NAT1 | protein_coding | tolerated(0.44) | benign(0.003) | TCGA-D8-A1Y0-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide+methotrexatum+fluorouracillum | SD | |
POMGNT2 | insertion | Frame_Shift_Ins | novel | c.14_15insAG | p.Val6GlyfsTer45 | p.V6Gfs*45 | Q8NAT1 | protein_coding | TCGA-A8-A090-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
POMGNT2 | insertion | Nonsense_Mutation | novel | c.34_35insCATGAGGT | p.Val12AlafsTer2 | p.V12Afs*2 | Q8NAT1 | protein_coding | TCGA-BH-A0E2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | ||
POMGNT2 | SNV | Missense_Mutation | rs536444876 | c.11N>T | p.Ser4Leu | p.S4L | Q8NAT1 | protein_coding | deleterious_low_confidence(0.04) | benign(0.043) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
POMGNT2 | SNV | Missense_Mutation | rs755067791 | c.76C>T | p.Arg26Cys | p.R26C | Q8NAT1 | protein_coding | tolerated_low_confidence(0.07) | benign(0) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
POMGNT2 | SNV | Missense_Mutation | c.100G>A | p.Glu34Lys | p.E34K | Q8NAT1 | protein_coding | deleterious_low_confidence(0.01) | benign(0.091) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
POMGNT2 | SNV | Missense_Mutation | rs769075803 | c.230G>A | p.Arg77His | p.R77H | Q8NAT1 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
POMGNT2 | SNV | Missense_Mutation | c.673C>T | p.Arg225Trp | p.R225W | Q8NAT1 | protein_coding | deleterious(0.01) | possibly_damaging(0.877) | TCGA-AA-3530-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
POMGNT2 | SNV | Missense_Mutation | rs749833091 | c.997N>T | p.Arg333Trp | p.R333W | Q8NAT1 | protein_coding | deleterious(0.01) | probably_damaging(0.91) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
POMGNT2 | SNV | Missense_Mutation | rs775667995 | c.1271N>A | p.Arg424His | p.R424H | Q8NAT1 | protein_coding | deleterious(0.05) | possibly_damaging(0.765) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |